Welcome to our dedicated page for Grifols S A news (Ticker: GRFS), a resource for investors and traders seeking the latest updates and insights on Grifols S A stock.
Grifols, S.A. reports developments tied to its global healthcare business, including plasma-derived medicines, diagnostic technologies, transfusion-medicine solutions and biological supplies for research, clinical trials and pharmaceutical or diagnostic manufacturing. Its business references include Biopharma, Diagnostic, Bio Supplies and other activities such as manufacturing services, research and complementary pharmaceutical products.
Recurring news themes include product and regulatory updates for plasma-protein therapies, such as fibrin sealant for surgical bleeding, and research programs that use plasma assets, AI, proteomics and real-world data. Coverage also includes Chronos-PD work led by Alkahest, shareholder communications on board composition and disclosure, and capital-market topics affecting Grifols' listed shares in Spain and the United States.
Grifols has announced the opening of the first AMBAR® Center in Barcelona, collaborating with Ace Alzheimer Center Barcelona. This center aims to collect real-world data from the AMBAR® clinical program, which uses periodic plasma exchange to slow cognitive and functional decline in Alzheimer's patients. The partnership aims to enhance the treatment and management of Alzheimer's with plans for future centers in the EU, U.S., and China. Over 35 million people globally suffer from Alzheimer's, emphasizing the significance of this innovation.
Grifols has partnered with the government of Andorra to create the Pyrenees Immunology Research Center (PYIRC), a modern facility aimed at advancing immunology research and therapy development. The center, set to open in 2023, will focus on immune system disorders, such as autoimmunity and cancer, and will attract international experts. Grifols will own 80% of the joint venture and invest approximately €25 million in construction, with €7 million in annual operating costs. This initiative aligns with Andorra's economic diversification goals in biotechnology and innovation.
Grifols announced a donation of 240 million international units of blood clotting factor medicines to the World Federation of Hemophilia from 2022 to 2030, bringing total contributions to over 440 million IU since 2014. This support aims to treat approximately 3,000 patients annually in developing countries, addressing global health inequities. Grifols' commitment reinforces its dedication to the hemophilia community and aligns with its mission to improve health access globally.
Grifols, S.A. (NASDAQ: GRFS), announced the filing of its 2020 Annual Report on Form 20-F with the SEC on April 9, 2021. This report includes audited financial statements for the fiscal year that ended on December 31, 2020. The Form 20-F can be accessed on both Grifols' website and the SEC's site. Shareholders can request a hard copy of the report, free of charge. Grifols is a global healthcare company focused on innovative solutions across its four divisions: Bioscience, Diagnostic, Hospital, and Bio Supplies, impacting the economy with EUR 7.5 billion and creating 140,000 jobs in 2020.
Grifols announced that its Phase 3 ITAC clinical trial for anti-coronavirus immunoglobulin did not achieve its primary endpoints. Despite this setback, the company is pursuing over 20 ongoing research efforts to identify COVID-19 treatment options. Grifols will collaborate on international studies involving intravenous and subcutaneous hyperimmune globulins for COVID-19 patients, along with evaluating other plasma-derived treatments. The trial enrolled nearly 600 patients across multiple countries, but the failure to meet primary endpoints raises concerns about the efficacy of the treatment.
Grifols (NASDAQ: GRFS) has announced the installation of its DG Reader Net semi-automated analyzer at ThedaCare Medical Center-Wild Rose in Wisconsin, marking its first in North America. This advanced system enhances pre-transfusion blood type compatibility testing by automating the reading of DG Gel cards, significantly reducing manual errors. The implementation will enable quicker results, crucial for timely blood transfusions in critical care settings. Grifols aims to improve patient safety and efficiency in laboratories, reinforcing its commitment to innovative diagnostic solutions.
Grifols has installed its first DG Reader Net semi-automated analyzer in North America at ThedaCare Medical Center-Wild Rose, Wisconsin. This innovative platform automates blood type compatibility testing, offering improved efficiency by providing results in minutes, crucial for critical care environments. The system minimizes manual errors by uploading results directly to the Laboratory Information System, enhancing patient safety. With a growing network of donation centers and a strong presence in the healthcare sector, Grifols continues to innovate in diagnostic solutions to improve healthcare delivery.
Grifols has finalized its agreement to acquire the remaining 56% of GigaGen for USD 80 million, strengthening its innovation strategy in biotherapeutics. GigaGen specializes in recombinant biotherapeutic medicines and has a promising pipeline, including GIGA-2050, an immunoglobulin for COVID-19, now entering Phase 1 trials in the U.S. The acquisition aligns with Grifols’ commitment to sustainable growth and expands its portfolio of advanced therapies, supporting patient health globally.
Grifols has finalized its acquisition of GigaGen for USD 80 million, securing 100% ownership. This move strengthens Grifols' innovation strategy, focusing on novel therapies derived from antibodies. GigaGen is recognized for its groundbreaking recombinant biotherapeutic medicines, including GIGA-2050, aimed at treating COVID-19, which is set for a Phase 1 trial. The acquisition aligns with Grifols' long-term growth plan and its commitment to integrating promising R&D projects.
Grifols, a leader in plasma-derived therapies, announced the launch of Plasmatology, the first scientific journal dedicated to plasma science, coinciding with the 70th anniversary of plasmapheresis. The journal, starting March 9, aims to become a key reference for plasma research and will publish peer-reviewed articles. Grifols will support the journal with an educational grant over two years. This initiative reflects the company's commitment to advancing plasma science and honors its founder's legacy in the field.